Copertina

A methodology to extract outcomes from routine healthcare data for patients with locally advanced non-small cell lung cancer

Abstract Background Outcomes for patients in UK with locally advanced non-small cell lung cancer (LA NSCLC) are amongst the worst in Europe. Assessing outcomes is important for analysing the effectiveness of current practice. However, data quality is inconsistent and regular large scale analysis is...

Descrizione completa

Salvato in:

Dettagli Bibliografici
Autori principali:	Swee-Ling Wong (Autore), Kate Ricketts (Autore), Gary Royle (Autore), Matt Williams (Autore), Ruheena Mendes (Autore)
Natura:	Libro
Pubblicazione:	BMC, 2018-04-01T00:00:00Z.
Soggetti:	article
Accesso online:	Connect to this object online.
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
di: Xia Luo, et al.
Pubblicazione: (2022)

Achievement of long-term local control after radiation and anti-PD-1 immunotherapy in locally advanced non-small cell lung cancer
di: Zhao Jing, et al.
Pubblicazione: (2021)

Evaluation of changes in tumor volume following upfront chemotherapy for locally advanced Non Small Cell Lung Cancer (NSCLC)
di: Omer Sager, et al.
Pubblicazione: (2021)

Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results
di: Candelaria Myrna, et al.
Pubblicazione: (2006)

Exploring the implications of modified advanced lung cancer inflammation index on outcomes in patients with advanced non-small cell lung cancer
di: Abhishek Mahajan, et al.
Pubblicazione: (2023)

Initial Systemic Treatment of Advanced Non-small Cell Lung Cancer
di: Muhammad Kamran Siddique, et al.
Pubblicazione: (2019)

Clinical development of nintedanib for advanced non-small-cell lung cancer
di: Takeda M, et al.
Pubblicazione: (2015)

The analysis of healthcare resources in patients with non-small cell lung cancer
di: Y. P. Yurkova, et al.
Pubblicazione: (2022)

PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
di: A. U. Kulikov
Pubblicazione: (2015)

Naples Prognostic Score as an Independent Predictor of Survival Outcomes for Resected Locally Advanced Non-Small Cell Lung Cancer Patients After Neoadjuvant Treatment
di: Zou Z, et al.
Pubblicazione: (2023)

Advanced Small Cell Lung Cancer with Cerebellar Metastases - A Case Report
di: Zhi Xiong Chong, et al.
Pubblicazione: (2015)

Advanced Small Cell Lung Cancer with Cerebellar Metastases - A Case Report
di: Zhi Xiong Chong, et al.
Pubblicazione: (2015)

Serum creatinine and cystatin C‐based diagnostic indices for sarcopenia in advanced non‐small cell lung cancer
di: Tianjiao Tang, et al.
Pubblicazione: (2022)

Short- and long-term outcomes in elderly patients with locally advanced non-small-cell lung cancer treated using video-assisted thoracic surgery lobectomy
di: Zhang L
Pubblicazione: (2018)

Immunotherapy for a POLE Mutation Advanced Non-Small-Cell Lung Cancer Patient
di: Yang Fu, et al.
Pubblicazione: (2022)

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
di: Enriqueta Felip, et al.
Pubblicazione: (2008)

Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
di: Le AD, et al.
Pubblicazione: (2017)

Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer
di: Thomas Rodier, et al.
Pubblicazione: (2022)

Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations
di: Yun Zhang, et al.
Pubblicazione: (2021)

GEMCITABINE / PLATINUM VS. VINORELBINE- PLATINUM IN PATIENTS WITH ADVANCED NON- SMALL- CELL LUNG CANCER
di: Deyan Davidov
Pubblicazione: (2008)

Skin manifestations of gefitinib and the association with survival of advanced non-small-cell lung cancer in Taiwan
di: Shiou-Han Wang, et al.
Pubblicazione: (2011)

Next Generation of Advanced Non-Small Cell Lung Cancer Therapy: Targeted and Immuno-Therapies
di: Sze Wah Samuel Chan, et al.
Pubblicazione: (2020)

Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China
di: Guiyuan Xiang, et al.
Pubblicazione: (2021)

A Bibliometric Analysis of Triptolide and the Recent Advances in Treating Non-Small Cell Lung Cancer
di: Quancheng Yang, et al.
Pubblicazione: (2022)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
di: Xiaomin Wan, et al.
Pubblicazione: (2021)

Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond
di: Xin Li, et al.
Pubblicazione: (2024)

Advances in Non-Small Cell Lung Cancer (NSCLC) Treatment-A Paradigm Shift in Oncology
di: Azhar Ali
Pubblicazione: (2024)

Mechanisms of Sepsis-Induced Acute Lung Injury and Advancements of Natural Small Molecules in Its Treatment
di: Yaxi Xu, et al.
Pubblicazione: (2024)

Redox Status in Patients with non-small Cell Lung Cancer in Advanced Stages Treated with Polychemotherapy
di: Gretel Riverón Forment, et al.
Pubblicazione: (2022)

CIMAvax-EGF®: Therapeutic Vaccine Against Non-small Cell Lung Cancer in Advanced Stages
di: Diana Rosa Fernández Ruiz, et al.
Pubblicazione: (2017)

Coping with methodological dilemmas; about establishing the effectiveness of interventions in routine medical practice
di: Frenken Rianne, et al.
Pubblicazione: (2006)

Advancing Primary Care in France and the United States
di: Thomas Ricketts, et al.
Pubblicazione: (2012)

Complete response to local therapy for advanced hepatocellular carcinoma with lung metastasis: a case report
di: Daeun Kim, et al.
Pubblicazione: (2022)

Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients
di: Peng Cao, et al.
Pubblicazione: (2022)

Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
di: Fenge Jiang, et al.
Pubblicazione: (2022)

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
di: Biagio Ricciuti, et al.
Pubblicazione: (2022)

Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer
di: Yi L, et al.
Pubblicazione: (2018)

Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
di: Jingsi Dong, et al.
Pubblicazione: (2019)

Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients
di: Cong Wang, et al.
Pubblicazione: (2018)

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
di: Rothschild SI
Pubblicazione: (2016)